TABLE 3.

Clinical features of 87 eyes with retinal vasculitis before and change in clinical features after receiving different regimens.

	Baseline, mean (95CI%)				Change, mean (95% CI)
	CT (n = 45)	ADA (n = 42)	p	Difference (95% CI)	CT (n = 45)	ADA (n = 42)	p	Difference (95% CI)
BCVA	0.47(0.37–0.57)	0.42(0.31–0.52)	0.484	0.05(−0.10–0.20)	0.06(−0.06–0.18)	0.33(0.21–0.46)	0.024*	0.28(0.11–0.45)
ACC grade	1.27(0.87–1.67)	1.51(1.09–1.93)	0.411	−0.24(−0.83 to 0.34)	−0.38(−0.85 to 0.09)	−1.22(−1.70 to −0.74)	0.017*	−0.84(−1.52 to −0.16)
Vitritis grade	0.94(0.68–1.19)	1.37(1.09–1.64)	0.027*	−0.43(−0.81 to −0.05)	−0.06(−0.45 to 0.33)	−1.37(−1.78 to −0.97)	<0.001*	−1.32(−1.88 to −0.75)
MT, μm	395.00(319.19–470.80)	347.95(267.59–428.30)	0.387	47.05(−61.68–155.79)	−102.90(−191.80 to −14.01)	−137.78(−224.52 to −51.03)	0.576	−34.88(−160.24 to 90.49)
FA score	21.47(19.57–23.36)	19.90(17.91–21.90)	0.259	1.56(−1.19–4.32)	−3.75(−6.35 to −1.15)	−12.85(−15.61 to −10.08)	<0.001*	−9.10(−12.92 to −5.27)

Abbreviation: BCVA, best −corrected visual acuity, ACC, Anterior chamber cell, MT, macular thickness, FA, fluorescein angiography, CI, confidence interval.

*p < 0.05. The primary outcome was the cumulative change from baseline in FA score of retinal vasculitis. The secondary outcomes consisted of cumulative changes in BCVA, ACC grade, vitritis grade, MT. Changes in clinical features are defined as post−treatment values subtracted from pre-treatment values. All means were derived from mixed models.